Skip to main content

2026 Call of the European ERA4Health Partnership – Prevent-OO

Image alluding to the ERA4Health Partnership - Prevent-OO

The European Partnership ERA4Health – Fostering a European Research Area for Health, of which the Foundation for Science and Technology (FCT) is a member, launched on November 13 the joint Call 2026 for funding research and innovation projects under the theme “Understanding and Preventing Overweight and Obesity (Prevent-OO).”

This Call the participation of funding institutions from 20 countries, with the aim of supporting collaboration on interdisciplinary research projects based on complementarity and the sharing of expertise in the field of obesity, with a clear translational research approach.

Applications should cover only one of the following topics:

  1. Understanding the causes of obesity and overweight and their complications through mechanistic research;
  2. Prevention and public health strategies for critical transition phases throughout life.

Applications may be submitted until January 21, 2026, at 11:00 a.m. (Mainland Portugal time).

To support potential candidates, an information sessionon November 18, between 9:00 a.m. and 11:00 a.m., with prior registration. A matchmaking event is also scheduled for November 21, between 12:00 p.m. and 2:00 p.m., with a view to facilitating the formation of transnational consortia. Registration is open until November 18 (inclusive). The times indicated are those of mainland Portugal.

For more information on the ERA4Health Call 2026, please visit the FCT website and the Call page.

The ERA4Health Partnership is co-funded under the Horizon Europe Framework Program and aims to establish flexible and effective coordination between funding agencies in the European Research Area, with a view to funding joint transnational R&I projects in priority areas of Health and Well-being. This partnership currently brings together 37 partners from 24 countries, including Portugal, represented by FCT and the Agency for Clinical Research and Biomedical Innovation (AICIB).